Wolverine Trading
HZNP

Wolverine Trading’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Wolverine Trading’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,600
Closed -$284K – 5250
2023
Q1 		$284K Sell
2,600
-17,500
-87% -$1.93M ﹤0.01% 3072
2022
Q4 		$2.29M Buy
+20,100
New +$1.67M ﹤0.01% 1307
2022
Q3 		– Sell
-10,300
Closed -$850K – 5701
2022
Q2 		$850K Sell
10,300
-11,000
-52% -$1.04M ﹤0.01% 2058
2022
Q1 		$2.25M Sell
21,300
-7,100
-25% -$692K ﹤0.01% 1659
2021
Q4 		$3.08M Buy
28,400
+21,300
+300% +$2.32M ﹤0.01% 1509
2021
Q3 		$780K Sell
7,100
-2,300
-24% -$239K ﹤0.01% 3333
2021
Q2 		$892K Sell
9,400
-13,100
-58% -$1.21M ﹤0.01% 2918
2021
Q1 		$1.96M Sell
22,500
-14,700
-40% -$1.24M ﹤0.01% 1948
2020
Q4 		$2.69M Buy
37,200
+8,700
+31% +$647K ﹤0.01% 1471
2020
Q3 		$2.23M Buy
28,500
+14,600
+105% +$1M 0.01% 1396
2020
Q2 		$768K Sell
13,900
-200
-1% -$8.56K ﹤0.01% 2273
2020
Q1 		$414K Sell
14,100
-4,800
-25% -$162K ﹤0.01% 2875
2019
Q4 		$681K Sell
18,900
-900
-5% -$27.6K ﹤0.01% 2782
2019
Q3 		$545K Sell
19,800
-23,300
-54% -$602K ﹤0.01% 2550
2019
Q2 		$1.04M Buy
+43,100
New +$1.09M ﹤0.01% 2008
2019
Q1 		– Sell
-19,600
Closed -$381K – 5695
2018
Q4 		$381K Buy
19,600
+2,100
+12% +$41.2K ﹤0.01% 2909
2018
Q3 		$343K Sell
17,500
-24,600
-58% -$468K ﹤0.01% 3578
2018
Q2 		$598K Hold
42,100
– – ﹤0.01% 2851
2018
Q1 		$598K Sell
42,100
-20,300
-33% -$300K ﹤0.01% 2851
2017
Q4 		$911K Buy
62,400
+30,100
+93% +$423K ﹤0.01% 2324
2017
Q3 		$410K Buy
32,300
+2,800
+9% +$35.6K ﹤0.01% 2861
2017
Q2 		$349K Buy
29,500
+1,700
+6% +$21.1K ﹤0.01% 2816
2017
Q1 		$417K Sell
27,800
-79,400
-74% -$1.29M ﹤0.01% 2608
2016
Q4 		$1.73M Buy
107,200
+30,000
+39% +$544K 0.01% 1454
2016
Q3 		$1.37M Buy
77,200
+6,300
+9% +$123K 0.01% 1590
2016
Q2 		$1.19M Buy
+70,900
New +$1.15M 0.01% 1460

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wolverine Trading's HZNP Position: Q3 2022 in Review

Wolverine Trading sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 4,854 shares — an estimated $400K sold.

Wolverine Trading first reported a position in HZNP in Q2 2016 and held it in 21 quarters. The position peaked at $2.64M in Q3 2020. 529 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

  • Wolverine Trading reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • Wolverine Trading sold 4,854 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $400K.
  • Wolverine Trading first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2016 and held it in 21 quarters.
  • Wolverine Trading's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.64M in Q3 2020.
  • 529 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Wolverine Trading's 13F filing for Q3 2022, filed 14 Nov 2022.